Complications of DFO therapy
Complication . | Experienced complication . | Did not experience complication . | P . |
|---|---|---|---|
| High-frequency hearing loss, no. (%) | 59 (18) | — | — |
| Vision/retinal, no. (%) | 19 (6) | — | — |
| Allergy, no. (%) | 6 (2) | — | — |
| Other, no. (%)* | 33 (10) | — | — |
| Severe local reactions, no. (%) | 28 (9) | 299 (91) | — |
| Stopped DFO, no. (%) | 8 (29) | 12 (4) | < .001 |
| Median ferritin, ng/mL | 3026 | 1634 | < .001 |
| Median HIC, mg/g dry weight liver | 9.8 | 7.8 | .27 |
| CVAD placement, no. (%) | 16 (56) | 57 (19) | < .001 |
Complication . | Experienced complication . | Did not experience complication . | P . |
|---|---|---|---|
| High-frequency hearing loss, no. (%) | 59 (18) | — | — |
| Vision/retinal, no. (%) | 19 (6) | — | — |
| Allergy, no. (%) | 6 (2) | — | — |
| Other, no. (%)* | 33 (10) | — | — |
| Severe local reactions, no. (%) | 28 (9) | 299 (91) | — |
| Stopped DFO, no. (%) | 8 (29) | 12 (4) | < .001 |
| Median ferritin, ng/mL | 3026 | 1634 | < .001 |
| Median HIC, mg/g dry weight liver | 9.8 | 7.8 | .27 |
| CVAD placement, no. (%) | 16 (56) | 57 (19) | < .001 |
— indicates did not experience.
The “other” category includes 6 patients in whom poor growth was attributed to DFO therapy, 4 with gastrointestinal symptoms, 3 with Yersinia infections, and 2 each with tinnitis, metaphysial dysplasia, and renal complications (failure and calculus).